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DNA repair and other protective responses to DNA damage.
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damage in skin cells.
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Figure 5

Frequency Distribution for Niacin Number in
the Maimo Diet and Cancer Study
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NAD Content of Non-Diseased Skin from
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WESTERN BLOT ANALYSIS OF P53 IN CELL EXTRACTS
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METHOD FOR ENHANCING PROTECTIVE
CELLULAR RESPONSES TO GENOTOXIC
STRESS IN SKIN

cals and ultraviolet light so that While the skin may be dam

aged, the underlying tissue is preserved. Biochemical mecha
nisms include the innate and acquired immune systems.

Microbiological pathogens are repelled by immune responses
at the epidermal level involving Langerhans cells, kerati
nocytes, cytokines, polynuclear cells, endothelial cells, mast
cells, and lymphocytes.

CROSS REFERENCE TO RELATED
APPLICATIONS

Structurally, the skin comprises epithelial tissue (the epi

This application is a divisional of application Ser. No.
09/765,129, ?led Jan. 18, 2001, now US. Pat. No. 6,552,050,
Which is a divisional of application Ser. No. 09/452,617, ?led
Dec. 1, 1999, now US. Pat. No. 6,337,065. This application

dermis) in the outer layer and beneath it, connective tissue

(the dermis), and beneath that, the fatty tissue (hypodermis).
The epidermis is not vasculariZed and regenerates every four
to six Weeks. Its primary function is to maintain the body’s
skin integrity, acting as a physical barrier to toxic agents, dirt,

claims bene?t of provisional patent application Ser. No.
60/110,482 ?led Dec. 1, 1998. The entire disclosure of pro

bacteria, microorganisms, and physical insults. The dermis is
beneath the epidermis and functions by providing strength,

visional patent application Ser. No. 60/ 110,482 is hereby

incorporated by reference.

support, blood, and oxygen to the skin. The principal cell
components of the dermis are ?broblasts although it also

BACKGROUND

contains sWeat glands, sebaceous glands, hair follicles, and
1. Field of the Invention
The invention is directed to methods and composition of

20

using organic molecules termed pro-NAD agents capable of

small fat cells. Hypodermis, also knoWn as the super?cial
fascia, attaches the dermis to the underlaying structures. Its
function is to promote an ongoing blood supply to the dermis

enhancing dermal and epidermal skin cell NAD content With
a resulting enhancement of DNA repair and other protective

for regeneration.

responses to genotoxic stress in skin.

and progressive process that beings from birth. Internal fac

2. Description of the Background
The present application relates to methods and composi
tions capable of modulating and upregulating the cellular
nicotinamide-adenine-dinucleotide (NAD) content by the
topical application of chemical agents for the purpose of
enhancing natural protective responses of skin cells to DNA
damage. The methods and compositions are effective for the
prevention and treatment of skin deterioration that results

The mechanisms of skin deterioration involve a gradual
25

tion. The consequences of internal deterioration can be
observed over the entire body from the skin to the internal
organs. While the mechanisms of internal deterioration are
30

as Well as atrophic sclerosis and other blemishes of skin. Skin
deteriorates With age as a natural consequence of prolonged
exposure to internal and external factors. Internal deteriora
tion factors include natural metabolic byproducts such as free
radicals Which cause the aging of all tissues. External dete

rioration factors include ioniZing radiation such as sunlight
and chemical insults such as pollution and cigarette smoke. In
theory, skin care methods and compositions should inhibit, or
sloW the process of skin deterioration by counteracting these
internal and external factors. Unfortunately, current methods
and compositions for skin care are generally reactive rather

not completely understood, somatic mutation has been shoWn
to be a contributing factor. Under the somatic mutation

theory, cells gradually lose their youthful characteristics and

from DNA damage to cells of the skin. The symptoms of such
skin deterioration are many and typically include the loss of

moisture, ?ne lines, deep lines, Wrinkles, and loss of elasticity

tors that contribute to skin aging include toxic metabolic

byproducts, autoimmune diseases, and genetic predisposi

35

their capacity to divide by the accumulation of mutations
(errors) in their genetic code. These mutations may be caused
by free radicals or alkylating agents generated in metabolism
that lead to unrepaired DNA damage. Over time, mutations
accumulate in the body until the cell can no longer divide or

produce functional proteins.
External factors such as chemical and physical agents in
40

the environment can also cause DNA damage that leads to

skin deterioration. The external factors include sunlight, pol
lution, and ingested chemicals from smoking or from food.
Deterioration of skin leads to changes in dermal thickness

than proactive. That is, current methods and compositions

and elasticity due to increased crosslinking of collagen. Epi
dermal regeneration increases in activity While metabolism,
sWeat glands, and vasculariZation, all decrease in activity. The
damage from internal and external factors is progressive and

reduce or obscure the signs of aging but have minimal or no

cumulative and results in the appearance of deterioration

45

effect on the underlying progressive and cumulative bio
chemical processes that cause skin deterioration. It is there
fore desirable to have a skin care method and composition

associated With aged skin.
50

Which not only reduce the symptoms of deterioration but also
treat the underlying causes of skin deterioration in such a Way
that deterioration can actually be retarded. To understand the
limitations of current methods and compositions, it is neces
sary to understand the function and structure of the skin and

results in DNA damage. In humans, oxidative stress and DNA
damage is caused by factors such as hyperbaric oxygen,

gamma radiation, ultraviolet radiation, oZone, peroxides, free
55

living in a loW pollution environment and avoiding sunlight,
they cannot be eliminated. Some factors like ioniZing radia

At ten pounds, the skin is the largest organ in the body. FIG.
1 shoWs a diagram of skin marking the location of the tWo

tion are present in all environments at a loW level and other
60

the dermal layer of the skin and keratinocytes located in the
epidermal layer of the skin. The skin provides the ?rst line of

can, to some extent, repel and absorb insults such as chemi

factors are byproducts of metabolism and cannot be totally

eliminated. Further, urban environments have high levels of
ground level pollution from a variety of sources that are not
likely to be reduced in the near future. HoWever, While DNA

defense betWeen the body’ s interior and harmful environmen

tal insults by Well established physical and biochemical
mechanisms. Physical protection mechanisms include the
relatively impermeable barrier the skin provides. The skin

radicals, alkylating agents, and redox cycling drugs. While
total oxidative stress and DNA damage may be reduced by

the mechanisms of skin deterioration.

major cell types present in skin, namely ?broblasts located in

Related to the somatic mutation theory, both internal and
external factors contribute to oxidative stress, Which in turn

65

damage cannot be avoided, not all DNA damage leads to
mutations.
DNA damage does not necessarily lead to mutation
because a normal cell contains diverse and effective systems

US 7,425,319 B2
3

4

for repairing damaged DNA. There are at least 50, and pos
sibly more than 100 genes involved in DNA repair. The

constant loW level environmental insults. That is, a sunblock
With an SPF factor of 15 Will not reduce photoaging 15 fold.
There is also a danger that chemicals in some sunblocks Will
increase DNA damage and contribute to skin deterioration.

importance of good DNA repair in retarding skin deteriora
tion is most noticeable in patients that suffer from DNA repair
defects such as xeroderrna pigmentosum @(P). XP have early

Finally, every major class of sunblock has been linked to skin

and accelerated skin deterioration, clearly demonstrating the
importance of DNA repair to reducing deterioration of the

allergies.

skin. In addition to DNA repair, a normal cell also has systems
that invoke “programmed cell deat ” by a process termed

agents. A physical blend is a mixture of tWo or more chemi

Finally, there are agents that are physical blends of existing

cals. Physical blends can be mixed poWders, mixed solutions,
mixed emulsions, mixed colloidal solutions, particles in solu

apoptosis. The process of apoptosis effectively “erases” cells
damaged beyond the point of repair. These natural defense

tions, and the like. An example of a physical blend may be a
covering or coloring cosmetic mixed With a sunblock (tita
nium dioxide) and a hydroxy acid.

mechanisms of the skin have been ignored by current meth
ods of preventing skin deterioration.

Many creams, lotions, bath oils, ointments, pastes, cleans

In summary, current methods of skin treatment are mostly

ers, covers, and poWders claim to be effective in preventing
skin deterioration. HoWever, all current methods and compo
sitions have severe disadvantages in that they are limited in
their ability to retard skin deterioration. Mo st over the counter
skin care products soften deteriorated skin or otherWise
reduce the symptoms of deteriorated skin With no effect on

reactive in that they treat the symptoms of deterioration after
the damage is done. Current skin treatment methods do not
reverse damage to the dermal tissue. There is a need for
topical skin care products that are proactive rather than reac

tive. A proactive product is one that Will assist the skin in
20

the underlying biochemical processes involved in deteriora
tion. Many existing skin care products and cosmetics function

by providing moisture to the skin, preventing moisture loss,
or providing cover to obscure the visible signs of deteriora
tion. While traditional cosmetics may have effects on appear
ance, these effects are evanescent and any apparent improve

resisting DNA damage by either preventing damage or assist
ing in repair of any damage.
SUMMARY OF THE INVENTION

25

The present invention overcomes many of the limitations,
problems and disadvantages associated With current strate

ment disappears as soon as the product use is discontinued.

gies and designs for preventing skin deterioration and pro

Further, traditional cosmetics’ effectiveness decrease upon
exposure to moisture and thus cosmetics must be reapplied
after exercise, sWimming, or any other exposure to moisture.
Some cosmetics contain metals (e.g., iron and copper) Which
may actually increase skin levels of free radical formation and
possibly promote deterioration. As the use of such products
does not prevent deterioration, more and more of the product

vides methods and composition for the treatment of skin
deterioration.
One object of the invention is directed to a method and
composition for treating skin to prevent and sloW the deterio
ration process.
It is another objective of the invention to provide a method
to retard deterioration of the skin by enhancing the skin’s
natural DNA repair mechanism.
It is another object of the invention to provide a method for
the sustained release of pro-NAD agents to skin cells.
Another object of the invention is directed to a composition
for topical application comprising one or more pro-NAD

is needed as time progresses to obscure the increasing severe

30

35

condition of the underlying skin.
Another method for treating aging skin is the use of alpha
hydroxy acids (AHA) such as lactic acid, citric acid, glycolic
acid, malic acids; beta hydroxy acids (BHA) such as salicylic

acid; and retinoids (e.g. tretinoin (retin A), retinol and reti

40

nal), as exfoliants. These agents help remove the uppermost
layer of skin to expose the more youthful underlying skin.

One embodiment of the invention is directed to a pharma
ceutical composition for a subject in need of an elevation of

HoWever, there is a danger that by removing the outer layer of
skin, AHA, BHA and retinoids can compromise the important
barrier function of skin. It is possible that the use of these

45

exfoliants may accelerate skin aging by removing the protec

cellular NAD in the subject. The pharmaceutical composition
maybe adapted for topical administration to the skin. Adap
tation may included the inclusion of a pharmaceutically
50

acceptable carrier Which is suitable for use in topical appli
cations.
The pro-NAD agents of the invention may comprise one or
more compounds With the folloWing formula:

disadvantage of AHA, BHA and retinoids is that these com
pounds are potential skin irritants Which can induce side
effects such as sore, red skin.

Another popular method for skin treatment is the use of

intracellular NAD content. The pharmaceutical composition
comprises a pro-NAD agent and a pharmaceutically accept
able carrier. The pro -NAD agent is present in the pharmaceu
tical composition at a concentration su?icient to elevate intra

tive outer layer of skin. Exfoliants and other ingredients may
also increase the skin’s sensitivity to environmental condi
tions such as sunlight, Wind, cold temperature and dry air, or
to chemical agents such as antigens, or may exacerbate the
irritation attributable to a pre-existing skin disease. Another

agent that promote cellular DNA repair.

55

sunblocks. Sunblock (i.e., sunscreen) refers to any chemical
that When applied to the skin, reduces the amount of UV light
that reaches the skin. By preventing UV absorptions that
cause genomic mutations, sunblocks can decrease and retard
skin deterioration. Sunblocks Were originally designed to
prevent sunburn (also knoWn as erythema), an acute reaction
to overexposure to the sun. The strength of sunblocks is

60

measured by the SPF index (Sun Protection Factor). An SPF
value of l 5, for example, Will provide 15 times the protection
of bare skin to sunburns. HoWever, it should be noted that the
SPF values, Which measures resistance to sunburn, cannot be

extrapolated to photoaging protection, Which is caused by

Where R1 is a hydrogen or any chemical group that can be
65

enZymatically or chemically removed to generate nicotinic
acid folloWing administration to said subject. A chemical
group is any chemical molecule such as, for example, any

US 7,425,319 B2
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5
branched or unbranched (straight) alkane, alkene, or alkyne

The pharmaceutical composition of the invention may

group. In a preferred embodiment, the chemical group is a

have a pro-NAD agent concentration that is betWeen about

group such as an ester, that can be removed by an esterase

0.001% to about 10% by Weight. Preferably, the pro-NAD
agent is betWeen about 0.01% and about 3% by Weight. The
pharmaceutical composition may further comprise an
optional agent such as, for example, antioxidants, sunscreens,

following the administration of the pharmaceutical composi
tion to the subject. Preferably, the esterase is an intracellular
esterase such that the chemical group is not removed until the
pro-NAD agent is inside a cell.
In a preferred embodiment, R1 is an unbranched or
branched chain alkane, alkene or alkyne of 1 carbon to about
30 carbon atoms, such as, for example betWeen about 14 and

vitamins, a pH stabiliZer, or a combination of these agents.

It is understood that the pharmaceutical composition of the
invention may be used for treating a subject. The subject is an
animal. The animal may be a unicellular or a multicellular

about 22 carbons. Rl may also contain one or more functional
groups. A functional group is an atom or group of atoms
acting as a unit, that has replaced a hydrogen atom in a

animal such as, for example, a mammal. Further, the mammal
may be a human. The subject may also be a cultured cell
population, a cultured cell line, an egg, a sperm or a Zygote.
Another embodiment of the invention is directed to a

hydrocarbon molecule and Whose presence imparts charac
teristic properties to a molecule. Examples of functional
groups that can be used include thiol, alcohol, amine, car

method for treating or for sloWing skin deterioration. In the
method, a pharmaceutical composition of the invention may

boxylic acid, onium, carboxylic anhydride, carboxylic ester,
acyl halide, amide, nitrile, aldehyde, ketone, imines, ethers,

be administered to a subject to treat, sloW or reverse skin

sul?de, halide, nitro, nitroso, aZides, diaZo, and a combina
tion of these groups.
In a preferred embodiment, Rl may be a chemical group

deterioration in the subject. Preferably, the method Will
20

increase the skin cell intracellular NAD concentration by at
least about 50% over an untreated subject. More preferably,
the method Will increase the intracellular NAD concentration
by an even greater amount such as, for example, by 100% over
an untreated subject. It is understood that skin cell in this

25

application refers to ?broblasts and/or keratinocytes. The
administration may be applied topically, intradermally or
subcutaneously. Topical administration may be via dermal

that changes the log PO/W of said pro-NAD agent to betWeen
about 5 to about 20.

In a preferred embodiment, the pro-NAD agent has a log
PO/W range betWeen about 5 to about 20. More preferably, the
pro-NAD agent has a log PO/W range betWeen about 10 to
about 15.
For example, the pro -NAD agent may be methylnicotinate,

patch or sloW release mechanism to the layer of skin of the
mammal. In addition, the administration may be oral or

ethylnicotinate, butylnicotinate, hexylnicotinate, octylnicoti
nate, tetradecylnicotinate, octadecylnicotinate or a combina
tion of these chemicals. A combination may be, for example,
at least one chemical selected from the group consisting of

30

parenteral.
Another embodiment of the invention is directed to a pro

cess for achieving transderrnal delivery of a pro-NAD agent.

methylnicotinate, ethylnicotinate, butylnicotinate, hexylni

In the process, an effective amount of a topical composition

cotinate, octylnicotinate and at least one chemical selected

comprising an effective amount of one or more pro-NAD

from the group consisting of tetradecylnicotinate and octade

35

cylnicotinate.

agent is applied to the skin of a subject. The pro-NAD agent
used in this process may be any pro-NAD agent discussed in

this application.

Alternatively, the pro-NAD agent may comprise one or
more compounds With the folloWing formula:

Another embodiment of the invention is directed to a pro
40

cess for reducing the cytotoxic effects of DNA damage in the
skin of a mammal by enhancing or elevating one or more skin

cell intracellular proteins. The skin cells are the ?broblasts

%

and/or keratinocytes in the skin. The process comprises

\N

applying to a layer of skin of the mammal an effective amount
45

of a pharmaceutical composition of the invention. The intra

cellular protein may be p53. Alternatively, the intracellular

protein may be PARP-l, PARP-2, PARP-3, tankyrase,

50

V-PARP and telomerase.
Another embodiment of the invention is directed to a
method for treating skin in order to inhibit skin deterioration
due to UV exposure. In the method, a pharmaceutical com
position of the invention is applied to the skin at a time
suf?ciently close to the time of UV exposure to inhibit UV

55

induced damage to the skin. The pharmaceutical composition
may be applied before UV exposure. Alternatively, the phar
maceutical composition maybe applied after UV exposure.
The time of application may be for example, less than 1 hour,

Where R2 is a hydrogen or a chemical group that can be

enZymatically or chemically removed to generate nicotina
mide after the pharmaceutical composition is administered.
For example, R2 may be a carboxylic acid containing an
alkane, alkene or alkyne of about 1 to about 30 carbon atoms.

Preferably, R2 is a carboxylic acid containing an alkane R
group With betWeen 14 and 22 carbons. In addition R2 also
contains one or more functional groups. The functional group

may be, for example, thiol, alcohol, amine, carboxylic acid,

less than 2 hour, less than 6 hour, less than 12 hour or less than

onium, carboxylic anhydride, carboxylic ester, acyl halide,
amide, nitrile, aldehyde, ketone, imines, ethers, sul?de,
halide, nitro, nitroso, aZides, or diaZo. Preferred functional
groups include thiol, alcohol, amine, and carboxylic acid

60

groups. R2 may also have more than one functional group.

Further, R2 may be any chemical group that changes the log
PO/W of said pro-NAD agent to betWeen about 5 to about 20.

Preferably, the pro-NAD agent has a log PO/W range betWeen
about 5 to about 20. More preferably, the pro-NAD agent has
a log PO/W range betWeen about 10 to about 15.

1 day before UV exposure. Alternatively, the time of appli
cation may be, for example, less than 5 minutes, less than 10
minutes, less than 20 minutes, less than 1 hour, less than 2
hours, less than 6 hours, less than 12 hours, less than 1 day,
less than 2 days, or less than 5 days after UV exposure.
Other embodiments and advantages of the invention are set

65

forth, in part, in the description Which folloWs and, in part,
Will be obvious from this description and understood by the
skilled artisan practicing this invention.

